bpc 157 benefits risks human studies Peptide BPC-157 BPC-157 Peptides in Orthopedics: What
Description
Clinical trials of AOD-9604 lasting up to 24 weeks demonstrated no cardiovascular adverse events and excellent overall tolerability
This is why our protocols at Perfect B are not single-compound prescriptions but layered combinations chosen for each patient
Regulatory note: Both BPC-157 and TB-500 are not FDA-approved for human use, and TB-500 is prohibited by WADA (class S2) for athletes
Prednisone to reduce platelet destruction, medicines to promote platelet synthesis in the bone marrow, and sometimes spleen excision are used to treat thrombocytopenia caused by autoimmune destruction of platelets (as in IPT)
